JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB272854

Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric)

5

(3 Reviews)

|

(5 Publications)

Human Recombinant Monoclonal SPIKE antibody. Suitable for ELISA, WB, FuncS (Neut/Block) and reacts with SARS-CoV-2, SARS-CoV samples. Cited in 5 publications.

View Alternative Names

2, S, Spike glycoprotein, S glycoprotein, E2, Peplomer protein

5 Images
Functional Studies (Neut/Block) - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)
  • FuncS (Neut/Block)

Supplier Data

Functional Studies (Neut/Block) - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)

Binding signal of Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (ab272854) and SARS-CoV-2-S1-RBD was inhibited by ACE2 protein-HRP conjugated inhibitor with the IC50 23.32 nM.

Functional Studies (Neut/Block) - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)
  • FuncS (Neut/Block)

Supplier Data

Functional Studies (Neut/Block) - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)

Binding signal of Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (ab272854) and SARS-CoV-2-S1-RBD was inhibited by ACE2 protein-HRP conjugated inhibitor with the IC50 2.38 μg/mL.

ELISA - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)
  • ELISA

Supplier Data

ELISA - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)

Binding Activity of ab272854 with SARS-CoV-2-S1-RBD
Activity : Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2-S1-RBD at 2 μg/ml can bind ab272854, the EC50 of SARS-CoV-2-S Antibody is 19.60-39.42 ng/ml.

ELISA - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)
  • ELISA

Supplier Data

ELISA - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)

Binding Activity of ab272854 with SARS-CoV-2 spike glycoprotein.
Activity : Measured by its binding ability in a functional ELISA. Immobilized SARS-CoV-2 spike glycoprotein at 2 μg/ml can bind ab272854. The EC50 of ab272854 is 36.79-48.87 ng/ml.

Western blot - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)
  • WB

Lab

Western blot - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (AB272854)

Lanes 1 - 8 : Merged signal (red and green). Green - ab272854 observed at 200 kDa. Red - loading control.

ab272854 was shown to react with SARS-CoV-2 spike glycoprotein in western blot. Membranes were blocked in 3% milk before incubation with ab272854 overnight at 4°C at 1 ug/ml. Blots were incubated with Donkey anti-Mouse IgG H&L(IRDye® 800CW) preabsorbed (ab216774) antibody at 1 in 20000 dilution for 1 hour at room temperature before imaging.

Note : ab216774 is suitable for the recognition of the Mouse scFv fragment of ab272854.

All lanes:

Western blot - Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (ab272854) at 1 µg/mL

Lane 1:

Mock transfected Expi cell lysate at 10 µg

Lane 2:

PDL-1 Flag transfected Expi cell lysate at 10 µg

Lane 3:

SARS-Cov1 spike protein transfected Expi cell lysate at 10 µg

Lane 4:

SARS-Cov1 3xFlag spike protein transfected Expi cell lysate at 10 µg

Lane 5:

SARS-Cov2 spike protein transfected Expi cell lysate at 10 µg

Lane 6:

SARS-Cov2 3xFlag spike protein transfected Expi cell lysate at 10 µg

Lane 7:

MERS Spike protein transfected Expi cell lysate at 10 µg

Lane 8:

MERS 3xFlag Spike protein transfected Expi cell lysate at 10 µg

Observed band size: 200 kDa

false

Key facts

Host species

Human

Clonality

Monoclonal

Clone number

H6

Isotype

IgG1

Carrier free

No

Reacts with

SARS-CoV, SARS-CoV-2

Applications

FuncS (Neut/Block), WB, ELISA

applications

Specificity

We have in-house data that suggests this product also reacts with SARS-CoV-1 spike protein in Western blot.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ELISA" : {"fullname" : "ELISA", "shortname":"ELISA"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "FuncSNeutBlock" : {"fullname" : "Functional Studies (Neut/Block)", "shortname":"FuncS (Neut/Block)"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "SARS-CoV": { "ELISA-species-checked": "guaranteed", "ELISA-species-dilution-info": "", "ELISA-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>", "FuncSNeutBlock-species-checked": "guaranteed", "FuncSNeutBlock-species-dilution-info": "", "FuncSNeutBlock-species-notes": "" }, "SARS-CoV-2": { "ELISA-species-checked": "testedAndGuaranteed", "ELISA-species-dilution-info": "1/10000 - 1/50000", "ELISA-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>", "FuncSNeutBlock-species-checked": "testedAndGuaranteed", "FuncSNeutBlock-species-dilution-info": "", "FuncSNeutBlock-species-notes": "<p></p>" } } }

Product details

Anti-SARS-CoV-2 spike glycoprotein antibody [H6] - Human IgG1 (Chimeric) (ab272854) is a recombinant human/mouse chimeric monoclonal antibody consisting of Mouse scFv fused with human IgG1.

As the Fc region is human, an anti-Human secondary antibody should be used for detection. A suitable anti-Mouse secondary may also be used.

Properties and storage information

Form
Liquid
Purity
undefined SDS-PAGE
Purification notes
Screened the positive clones from mouse ScFv antibody libraries, then expressed in 293F cells.
Storage buffer
pH: 7.4 Preservative: 0.03% Proclin 300 Constituents: PBS, 50% Glycerol (glycerin, glycerine)
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The SARS-CoV-2 Spike Glycoprotein also known as COVID-19 Spike Protein is a trimeric protein weighing approximately 180-200 kDa. It is located on the surface of the SARS-CoV-2 virus playing an important role in virus infectivity. The protein comprises two main subunits S1 and S2 which facilitate attachment to and fusion with host cells. The S1 subunit contains the receptor binding domain (RBD) which specifically binds to the human angiotensin-converting enzyme 2 (ACE2) receptor. The Spike Glycoprotein is expressed in infected host cells mainly in the respiratory tract allowing the virus to enter and initiate replication.
Biological function summary

The SARS-CoV-2 Spike Glycoprotein initiates viral entry by interacting with the host cell's ACE2 receptor which leads to viral fusion and entry into the cell's cytoplasm. The protein is part of the virion structure and forms the visible spike on the virion's surface. Upon binding a conformational change triggers the fusion of viral and cellular membranes a vital step for the viral lifecycle. The multimeric nature of the Spike Protein facilitates its interaction with antibodies including those known as 'anti-spike antibodies' which can neutralize the virus and prevent cell infection.

Pathways

The Spike Glycoprotein plays a significant role in the viral infection process and immune response pathways. It is central to the receptor-mediated endocytosis pathway where the virus is internalized into host cells. The protein’s interaction with ACE2 modifies downstream signaling pathways potentially altering host cell functions. Related proteins in these pathways include the ACE2 receptor and the cellular protease TMPRSS2 which primes the Spike Protein for fusion and viral entry.

The Spike Glycoprotein is chiefly implicated in COVID-19 the disease caused by SARS-CoV-2. The interaction with ACE2 is not just vital for infection but also contributes to the disease's symptomatology as ACE2 is involved in regulating blood pressure and inflammation. Additionally the Spike Protein's role in viral entry makes it a target for therapeutic interventions including 'anti-spike antibodies' and vaccines aimed at blocking this process to prevent infection. The protein's relevance to COVID-19 has led to significant interest in developing diagnostic and therapeutic tools such as 'antibodies COVID' that target the Spike Glycoprotein to manage the disease effectively.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Spike protein S1. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2 (PubMed : 32142651, PubMed : 32155444, PubMed : 33607086). When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane (PubMed : 34561887). When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis leading to fusion of the virion membrane with the host endosomal membrane (PubMed : 32075877, PubMed : 32221306). Alternatively, may use NRP1/NRP2 (PubMed : 33082294, PubMed : 33082293) and integrin as entry receptors (PubMed : 35150743). The use of NRP1/NRP2 receptors may explain the tropism of the virus in human olfactory epithelial cells, which express these molecules at high levels but ACE2 at low levels (PubMed : 33082293). The stalk domain of S contains three hinges, giving the head unexpected orientational freedom (PubMed : 32817270).. Spike protein S2. Precursor of the fusion protein processed in the biosynthesis of the S protein and the formation of virus particle. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains two viral fusion peptides that are unmasked after cleavage. The S2/S2' cleavage occurs during virus entry at the cell membrane by host TMPRSS2 (PubMed : 32142651) or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change leading to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.. Spike protein S2'. Subunit of the fusion protein that is processed upon entry into the host cell. Mediates fusion of the virion and cellular membranes by functioning as a class I viral fusion protein. Contains a viral fusion peptide that is unmasked after S2 cleavage. This cleavage can occur at the cell membrane by host TMPRSS2 or during endocytosis by host CSTL (PubMed : 32703818, PubMed : 34159616). In either case, this triggers an extensive and irreversible conformational change that leads to fusion of the viral envelope with the cellular cytoplasmic membrane, releasing viral genomic RNA into the host cell cytoplasm (PubMed : 34561887). Under the current model, the protein has at least three conformational states : pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of the viral and target cell membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-hairpins structure and position the fusion peptide in close proximity to the C-terminal region of the ectodomain. Formation of this structure appears to promote apposition and subsequent fusion of viral and target cell membranes.
See full target information S

Publications (5)

Recent publications for all applications. Explore the full list and refine your search

Heliyon 10:e30044 PubMed38698981

2024

Conditional reprogrammed human limbal epithelial cell model for anti-SARS-CoV-2 drug screening.

Applications

Unspecified application

Species

Unspecified reactive species

Yu Xiao,Ling Wang,Shi-Xu Li,Shi-Song Fang,Fan Luo,Shu-Liang Chen,Xuan Zou,Lin Ye,Wei Hou

Vaccines 11: PubMed38005972

2023

Gag Virus-like Particles Functionalized with SARS-CoV-2 Variants: Generation, Characterization and Recognition by COVID-19 Convalescent Patients' Sera.

Applications

Unspecified application

Species

Unspecified reactive species

Arnau Boix-Besora,Francesc Gòdia,Laura Cervera

International journal of molecular sciences 23: PubMed36142365

2022

Proteomic Analysis Identifies Molecular Players and Biological Processes Specific to SARS-CoV-2 Exposure in Endothelial Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Thatiana Corrêa de Melo,Dilza Trevisan-Silva,Miryam P Alvarez-Flores,Renata Nascimento Gomes,Marcelo Medina de Souza,Hellen Paula Valerio,Douglas S Oliveira,Carlos DeOcesano-Pereira,Viviane Fongaro Botosso,Soraia Attie Calil Jorge,Mirta Schattner,Ricardo M Gomez,Ana Marisa Chudzinski-Tavassi

RSC advances 12:16184-16193 PubMed35733688

2022

Inhibition of SARS-CoV-2 spike protein entry using biologically modified polyacrylonitrile nanofibers: study towards specific antiviral masks.

Applications

Unspecified application

Species

Unspecified reactive species

Merna H Emam,Hassan Nageh,Fedaa Ali,Mohamed Taha,Hasnaa A ElShehaby,Rehab Amin,Elbadawy A Kamoun,Samah A Loutfy,Amal Kasry

Vaccines 10: PubMed35214708

2022

Optimization, Production, Purification and Characterization of HIV-1 GAG-Based Virus-like Particles Functionalized with SARS-CoV-2.

Applications

Unspecified application

Species

Unspecified reactive species

Arnau Boix-Besora,Elianet Lorenzo,Jesús Lavado-García,Francesc Gòdia,Laura Cervera
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com